---
figid: PMC7961376__ijms-22-02625-g001
figtitle: Molecular pathways of novel emerging targets in NSCLC and agents in clinical
  development
organisms:
- Homo sapiens
- unidentified
- Juniperus communis
pmcid: PMC7961376
filename: ijms-22-02625-g001.jpg
figlink: pmc/articles/PMC7961376/figure/ijms-22-02625-f001/
number: F1
caption: Molecular pathways of novel emerging targets in NSCLC and agents in clinical
  development. Several molecular pathways are physiologically activated by the interactions
  between circulating growth factors (colored circles) and trans-membrane receptors
  (colored sticks crossing the cell membrane), which result in the downstream activation
  of intracellular proteins (colored ovoids) associated with cell proliferation, increased
  aggressiveness, or immune escape. The details for each individual pathway are described
  in the appropriate paragraphs. Molecular alterations (e.g., gene fusions) potentially
  associated with tumorigenesis are reported next to the relevant molecule. When available,
  investigational agents able to inhibit specific pathways are reported (blank boxes),
  with reference to the specifically targeted molecule or interaction.
papertitle: Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
reftext: Sara Elena Rebuzzi, et al. Int J Mol Sci. 2021 Mar;22(5):2625.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7733237
figid_alias: PMC7961376__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7961376__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7961376__ijms-22-02625-g001.html
  '@type': Dataset
  description: Molecular pathways of novel emerging targets in NSCLC and agents in
    clinical development. Several molecular pathways are physiologically activated
    by the interactions between circulating growth factors (colored circles) and trans-membrane
    receptors (colored sticks crossing the cell membrane), which result in the downstream
    activation of intracellular proteins (colored ovoids) associated with cell proliferation,
    increased aggressiveness, or immune escape. The details for each individual pathway
    are described in the appropriate paragraphs. Molecular alterations (e.g., gene
    fusions) potentially associated with tumorigenesis are reported next to the relevant
    molecule. When available, investigational agents able to inhibit specific pathways
    are reported (blank boxes), with reference to the specifically targeted molecule
    or interaction.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GDNF
  - NRTN
  - ARTN
  - PSPN
  - NGF
  - NTF4
  - HGF
  - IL6
  - SOS1
  - CDH1
  - FZR1
  - NTRK1
  - NTRK2
  - NTRK3
  - RET
  - ERBB2
  - KRAS
  - NRAS
  - PES1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - GEN1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - MTOR
  - MAN2C1
  - EPHB2
  - MAPK1
  - MAPK3
  - RHO
  - RHOD
  - RHOA
  - RHOB
  - RHOC
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MMP2
  - MMP1
  - MMP3
  - MMP7
  - MMP8
  - MMP9
  - MMP10
  - MMP11
  - MMP12
  - MMP13
  - MMP14
  - MMP15
  - MMP16
  - MMP17
  - MMP19
  - MMP20
  - MMP21
  - MMP23B
  - MMP24
  - MMP25
  - MMP26
  - MMP27
  - MMP28
  - CCND1
  - CCND2
  - CCND3
  - CDK6
  - CDK4
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK5
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - Capmatinib
  - Poziotinib
  - Tepotinib
  - Pyrotinib
  - Mobocertinib
  - Savolitinib
  - Selpercatinib
  - Pralsetinib
  - Criaotinib
  - Trametinib
  - Momelotinib
  - Selumetinib
---
